focus -WSS

focus

author：leisure time 2025-09-28 08:31:28 - browse：83449

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Longer MASH drug regimen improved liver, Akero study finds

knowledge

WSS

Biden's 'march

Florida health officials providing scant details on measles cases

Immune cells and nerve overgrowth may explain recurring UTI pain

Dozens dead from Maui wildfires: What we know about the victims

Florida health officials providing scant details on measles cases

Maui wildfire now ranks as the fifth

explore

focus

focus

How to save PrEP access — and even expand it

Bird flu researchers hone in on Finland’s mink farms

Duchenne breakthrough therapy leaves behind pioneering families

Pregnant women don't need prenatal multivitamins, study concludes

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Illumina slashes 2023 revenue projections yet again

23andMe had bad news about my health. I wish a person had delivered it

What to know about the judge who will handle the Trump case

Moonlake's readout produced a cash windfall. Risks remain

Montana youths win climate lawsuit against state for promoting fossil fuels

entertainment

The public health thinking behind the CDC’s new Covid guidance

Florida health officials providing scant details on measles cases

Montana youths win climate lawsuit against state for promoting fossil fuels

Stem cell biologist probes earliest stages of human development

The public health thinking behind the CDC’s new Covid guidance

Schizophrenia gene found to be linked to cells' energy dysfunction

entertainment

knowledge

leisure time

explore